A Multicenter, Open-Label Single-Arm Study of YONDELIS (trabectedin) for Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Excluding Leiomyosarcoma and Liposarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment
The purpose of this study is to determine if the study vaccine in combination with OPT-821 works better then OPT-821 alone in preventing reccrurance of patient's metastic soft tissue sarcoma.
* Subject's must have stage IV sarcoma with either newly dianosed or distant relapsed disease
* Subject's must have had surgical mastectomy within 8 weeks of starting treatment that rendered them radiographically disease free
*Subject's with locally recurrant disease only are not eligible
* Subject's must be 16 or older
18 - 100
Healthy Volunteers Needed
Duration of Participation
Approximately 4 months on average
Clinical Trials Information Line: Phone 503-494-1080 or email@example.com
Janssen Pharmaceutical Research & Development, L.L.C.